SEC Form 4 · accession 0001179022-18-000039
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter G Traber
Officer — President & CEO
Period of report
May 22, 2018
Accepted (ET)
May 24, 2018 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $4.16 | May 22, 2018 | A | 125,000 | A | — | May 22, 2028 | Common Stock | 125,000 | 125,000 | D |
Explanation of responses
- F1The options vest as follows: 25% on June 30, 2018, 25% on September30, 2018, and 50% on December 31, 2018.